Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs

Publication
Video
Special ReportsGastrointestinal Cancers: mCRC (Issue 7)
Volume 1
Issue 7

The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Jonathan R. Strosberg, MD, medical oncologist, Moffitt Cancer Center, discusses the results of the phase III NETTER-1 trial. The trial looked at radionuclide therapy Lu-Dotatate (177Lutetium DOTATATE; Lutathera) in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Articles in this issue
Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancer
Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancer
ERCC1 Expression Falls Short as Chemo Biomarker in mCRC
ERCC1 Expression Falls Short as Chemo Biomarker in mCRC
Panitumumab Boosts Overall Survival in Chemorefractory mCRC
Panitumumab Boosts Overall Survival in Chemorefractory mCRC
Dr. Katherine Van Loon on Recognizing Recurrences in Gastrointestinal Cancers
Dr. Katherine Van Loon on Recognizing Recurrences in Gastrointestinal Cancers
Two Options Allows for Treatment Tailoring in Refractory CRC
Two Options Allows for Treatment Tailoring in Refractory CRC
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
Dr. Manish A. Shah on BBI608 in the Treatment Paradigm for Gastrointestinal Cancers
Dr. Manish A. Shah on BBI608 in the Treatment Paradigm for Gastrointestinal Cancers
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRC
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRC
Recent Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs

Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs

Tim Cortese
January 21st 2025
Article

The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.

Read More

LaPelusa’s Journey in the Dynamic Field of GI Oncology

LaPelusa’s Journey in the Dynamic Field of GI Oncology

Jordyn Sava;Michael LaPelusa, MD
May 1st 2024
Podcast

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

Can ChatGPT Prove Its Effectiveness in Health Care?

Can ChatGPT Prove Its Effectiveness in Health Care?

Grace Koennecke
January 19th 2025
Article

A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training to use AI effectively.

Read More

Unpacking the Latest Research in Gastrointestinal Cancers

Unpacking the Latest Research in Gastrointestinal Cancers

Nichole Tucker;Benjamin L. Schlechter, MD
February 15th 2023
Podcast

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Listen

Emerging BsAbs and Their Impact in Multiple Myeloma

Emerging BsAbs and Their Impact in Multiple Myeloma

Morgan Bayer
January 17th 2025
Article

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

Read More

Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer

Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer

Jonah Feldman
January 17th 2025
Article

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.

Read More